Endocrine Abstracts

Pasireotide long-acting release (LAR) is a multireceptor-targeted somatostatin receptor ligand approved for treatment of patients with acromegaly. In some clinical reports, pasireotide LAR has been shown to regulate biochemical outcomes more than other somatostatin receptor ligands. However, hyperglycemia was frequently observed in pasireotide LAR treated patients with acromegaly. Three patients were treated with pasireotide LAR to regulated biochemical parameters of acromegal...

Objective: Although the importance of islet α-cell dysfunction in the pathogenesis of type 2 diabetes has been reappraised, data on whether increase or decrease of glucagon relative to insulin is related with glucose metabolism parameters or metabolic diseases such as nonalcoholic fatty liver disease(NAFLD) in clinical settings are very limited. Therefore, we investigated the association between glucagon-to-insulin ratio(G/I ratio) and presence of NAFLD and metabolic para...

Objective: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium – glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes(T2D) at high CV risk. SGLT2-i should be considered as a valuable therapy in T2D with established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF). We analyzed the effects of cardiovascular function of SGLT 2 inhibitors in T2D with ASCVD or HF compared with dipeptidyl peptidase-4...

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the efficacy of dapagliflozin in type 2 diabetic patients. We evaluated the efficacy and safety of body weight reduction of dapagliflozin in real practice with type 2 diabetes in Korea.Methods: This is a retrospective, observational study, data from 61 patients ...

Objective: This study was performed to determine the impact on quality of life and sleep impairment of painful diabetic peripheral neuropathy (PDPN).Research design and method: The study pool consisted of 200 randomly selected peoples with type 2 diabetic peripheral neuropathy. PDPN was diagnosed using visual analogue scales (VAS) and medical history. The patients were asked to answer the Brief Pain Inventory-Short Form (BPI-SF), Medical Outcomes Study S...

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the glycemic efficacy on a combination of dapagliflozin in type 2 diabetic patients in Korean. We evaluated the efficacy and safety of glucose control on a combination of dapagliflozin in people with type 2 diabetes in Korea.Methods: This is a retrospective, obs...